Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors

NCT00356889 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

NIH

Sponsor class

Conditions

Cholangiocarcinoma of the Extrahepatic Bile Duct
Cholangiocarcinoma of the Gallbladder
Gastrointestinal Cancer
Recurrent Extrahepatic Bile Duct Cancer
Recurrent Gallbladder Cancer
Unresectable Extrahepatic Bile Duct Cancer
Unresectable Gallbladder Cancer

Interventions

DRUG: erlotinib hydrochloride
BIOLOGICAL: bevacizumab

Sponsor

National Cancer Institute (NCI)